PTC Therapeutics, Inc. (PTCT)
| Market Cap | 5.83B |
| Revenue (ttm) | 1.73B |
| Net Income (ttm) | 682.64M |
| Shares Out | 82.91M |
| EPS (ttm) | 7.78 |
| PE Ratio | 9.03 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,925,705 |
| Open | 69.96 |
| Previous Close | 69.22 |
| Day's Range | 66.34 - 70.59 |
| 52-Week Range | 35.95 - 87.50 |
| Beta | 0.55 |
| Analysts | Buy |
| Price Target | 80.65 (+14.79%) |
| Earnings Date | May 7, 2026 |
About PTCT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for PTCT stock is "Buy." The 12-month stock price target is $80.65, which is an increase of 14.79% from the latest price.
News
PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam
- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose - - Continued evidence of favorable safety profile - - Novartis i...
PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study
WARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call today, April 28 at 4:30 p.m.
PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026
WARREN, N.J., April 22, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2026 financial resul...
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., April 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2026, the company approved non-statutory stock options to purchase an aggregate of ...
PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors
WARREN, N.J., March 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the appointment of Jessica Chutter to its Board of Directors.
PTC Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
Sepiapterin’s launch for PKU has seen rapid adoption, strong early revenues, and broad patient benefit, with global expansion underway and low discontinuation rates. The pipeline is advancing, notably in Huntington’s disease, with multiple early-stage programs moving toward the clinic.
PTC Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Sephience's global launch for PKU exceeded expectations, with broad patient uptake, high adherence, and strong financial performance. The pipeline is advancing with new formulations, ongoing studies, and promising programs in FA and HD, while the company pursues both internal development and strategic partnerships.
PTC Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Sephience's global launch drove rapid revenue growth and broad patient adoption, with strong financial performance and disciplined expense management positioning the company for cash flow break even in 2026. Pipeline progress includes late-stage Huntington's and Friedreich's ataxia programs, while early-stage R&D and global expansion remain key priorities.
PTC Therapeutics to Participate at Upcoming Investor Conferences
WARREN, N.J., Feb. 23, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: TD Cowen 46th Annual Health Care Conferen...
PTC Therapeutics Earnings Call Transcript: Q4 2025
Sephience's global launch drove strong 2025 revenue, exceeding guidance and establishing broad adoption across patient segments. Robust cash position and disciplined OpEx set up for 19%-36% revenue growth in 2026, with international expansion and R&D progress expected.
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
– Full-year 2025 product and royalty revenue of $831M, exceeding guidance – – Strong Sephience™ (sepiapterin) uptake since 2H 2025 launch with fourth quarter and 2025 revenue of $92M and $111M, respec...
PTC Therapeutics Provides Regulatory Update on Translarna™
WARREN, N.J., Feb. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has withdrawn the New Drug Application (NDA) resubmission for Translarna™ (ataluren) for the t...
PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026
WARREN, N.J., Feb. 5, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its fourth quarter and full year 2025 fi...
PTC Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
BillionToOne reported rapid revenue growth, high gross margins, and GAAP profitability, driven by its patented single molecule sequencing platform and differentiated prenatal and oncology products. 2026 revenue guidance was raised to $415–$430 million, with oncology expected to outpace prenatal growth.
PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
– Strong Sephience™ (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M – – Unaudited 2025 total product and royalty revenue of approximately $823M, exceeding guidance – – 2026 p...
PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan
– Indication includes all ages and the full spectrum of disease severity – – First Japan product approval for PTC – WARREN, N.J. , Dec. 22, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) a...
PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
WARREN, N.J. , Dec. 18, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B.
PTC Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025
Sephience’s global PKU launch shows rapid adoption and strong patient enthusiasm, driven by its unique clinical profile and support infrastructure. The company is expanding manufacturing, managing pricing, advancing R&D, and maintaining expense discipline. Regulatory engagement and partnerships support growth and future launches.
PTC Therapeutics Transcript: R&D Day 2025
A focused R&D strategy has advanced proprietary splicing and ferroptosis platforms, yielding multiple late- and early-stage programs with strong preclinical and clinical validation. The PTSeek platform accelerates discovery of novel RNA modulators, while disciplined resource allocation and strategic partnerships support sustainable growth and commercialization plans.
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoag...
Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600
NEW YORK , Nov. 24, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: S&P SmallCap 600 constituent Sandisk Corp. (NASD: SNDK) will replace T...
PTC Therapeutics to Host R&D Day
Event to take place on Dec. 2, 2025 in New York City WARREN, N.J. , Nov. 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will host an R&D Day to discuss its pipe...
PTC Therapeutics Transcript: Jefferies London Healthcare Conference 2025
SEPHIENCE's global launch for PKU has seen rapid adoption, strong initial revenues, and broad prescriber enthusiasm, with minimal payer restrictions and a focus on maintaining pricing integrity internationally. The pipeline remains robust, with key programs advancing and profitability expected soon.
PTC Therapeutics Transcript: UBS Global Healthcare Conference 2025
Sephience's launch in PKU has seen rapid adoption and strong early revenue, with broad patient and prescriber engagement and favorable payer access. International expansion is underway, and the pipeline includes regulatory discussions for vatiquinone and a major Huntington's partnership.
PTC Therapeutics Earnings Call Transcript: Q3 2025
Third quarter revenue reached $211 million, led by the strong global launch of Sephience, which generated $19.6 million and saw broad uptake across all PKU patient segments. Full-year revenue guidance was narrowed to $750–$800 million, and the company ended the quarter with $1.68 billion in cash.